Medical economics and the assessment of value in cardiovascular medicine: Part II.
Mark
Daniel B
DB
Outcomes Research and Assessment Group, Duke Clinical Research Institute, Durham, NC 27715, USA. daniel.mark@duke.edu
Hlatky
Mark A
MA
D015906:Angioplasty, Balloon, Coronary / Q000191:economics; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000191:economics* / Q000517:prevention & control / Q000628:therapy*; D001026:Coronary Artery Bypass / Q000191:economics; D003362:Cost-Benefit Analysis; D004470:Economics, Medical / Q000592:standards* / Q000639:trends; D006801:Humans; D009204:Myocardial Revascularization / Q000191:economics; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D015607:Stents
D000924:Anticholesteremic Agents; D010975:Platelet Aggregation Inhibitors